Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635299 | 0.84 | DRD2 (0.51) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL499011 | 0.83 | DRD2 (0.50) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL1634702 | 0.83 | DRD2 (0.47) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL498725 | 0.83 | TTR (0.48) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL6493962 | 0.83 | ATM (0.47) | DRD2CA2ATMKDM4EALDH1A1 | |
| Bromide SCHEMBL27499821 | 0.82 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL7631655 | 0.81 | DRD2 (0.48) | DRD2CA2ATMKDM4EPOLB | |
| SCHEMBL3119147 | 0.80 | DRD2 (0.56) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL6663695 | 0.80 | DRD2 (0.53) | DRD2CA2ATMKDM4EALDH1A1 | |
| SCHEMBL27442665 | 0.80 | CA2 (0.71) | CA2ATMKDM4EALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853270-B2 | Substituted stilbenes and their reactions | UNIVERSITY OF SALFORD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20130023663-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | HADFIELD JOHN ANTHONY (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20070203217-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) | 2007-08-30 | — | — | US | disclosed |
| US-7220784-B2 | Substituted stilbenes and their reactions | CANCER RESEARCH VENTURES LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | CANCER RESEARCH VENTURES LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1351912-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | Cancer Research Ventures Limited (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002050007-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023663-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | BLVRB, BBOX1, SQLE | DRD2 3289/4885CA2 521/4885ATM 2958/4885 |
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | QPCT, PAM, AURKB | DRD2 3741/4885CA2 820/4885ATM 2589/4885 |
| US-20070203217-A1 | SUBSTITUTED STILBENES AND THEIR REACTIONS | CASP4, ATG4B, CTSB | DRD2 3178/4885CA2 514/4885ATM 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.